

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 03-344-J (400/110US))

In the Application of:)
McSwiggen et al.)
Serial No.: 10/553,729)
Filing Date: March 6, 2007)
For: RNA Interference Mediated Inhibition of)
Severe Acute Respiratory Syndrome)
(SARS) Gene Expression Using Short)
Interfering Nucleic Acid)
Examiner: TBD
Group Art Unit: 1632
Confirmation No.: 5884

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Sections 1.56 and 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. In accordance with Rule 37 CFR §1.98(d), all numbered references are submitted herein. All references cited are also listed in the PTO-1449 form enclosed herewith.

Portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief is in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff LLP

Date: August 16, 2007

By: Michael S. Greenfield/
Michael S. Greenfield
Reg. No. 37,142

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive
Chicago, IL 60606
Telephone: 312-913-0001
Facsimile: 312-913-0002